Skip to main content

Advertisement

Table 1 Demographic and clinical characteristics

From: Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies

  EINSTEIN-DVT[8] EINSTEIN-PE[9] EINSTEIN pooled
  Rivaroxaban Enoxaparin/VKA Rivaroxaban Enoxaparin/VKA Rivaroxaban Enoxaparin/VKA
  (N = 1731) (N = 1718) (N = 2419) (N = 2413) (N = 4151) (N = 4131)
Male sex–n (%) 993 (57.4) 967 (56.3) 1309 (54.1) 1247 (51.7) 2302 (55.5) 2214 (53.6)
Mean age–years ± SD 55.8 ± 16.4 56.4 ± 16.3 57.9 ± 7.3 57.5 ± 7.2 57.0 ± 17.0 57.0 ± 16.8
Risk factor associated with VTE–n (%)       
  Recent surgery or trauma 338 (19.5) 335 (19.5) 415 (17.2) 398 (16.5) 753 (18.1) 733 (17.7)
  Previous VTE 336 (19.4) 330 (19.2) 455 (18.8) 489 (20.3) 791 (19.1) 819 (19.8)
  Active cancer 118 (6.8) 89 (5.2) 114 (4.7) 109 (4.5) 232 (5.6) 198 (4.8)
  Estrogen therapy 140 (8.1) 115 (6.7) 207 (8.6) 223 (9.2) 347 (8.4) 338 (8.2)
  Immobilization 265 (15.3) 260 (15.1) 384 (15.9) 380 (15.7) 649 (15.6) 640 (15.5)
  Known thrombophilic condition 107 (6.2) 116 (6.8) 138 (5.7) 121 (5.0) 245 (5.9) 237 (5.7)
  Unprovoked VTE 1055 (60.9) 1083 (63.0) 1566 (64.7) 1551 (64.3) 2621 (63.1) 2634 (63.8)
Duration of study treatment–days (mean [SD])* 193.6 (89.3) 187.5 (92.5) 216.3 (98.7) 214.3 (98.9) 207.6 ± 95.9 203.8 ± 97.4
  1. *Duration of actual study treatment after randomization until end of treatment (safety population).
  2. SD Standard deviation, VKA Vitamin K antagonist, VTE Venous thromboembolism.